...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepato-gastroenterology. >Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
【24h】

Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.

机译：结肠腺癌患者血清，尿液和组织中的组织蛋白酶D和癌胚抗原。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND/AIMS: Application of neoplastic markers in early diagnosis of colorectal carcinoma has brought fresh hope to millions of sufferers. However such a marker, distinctive for this particular carcinoma and allowing its detection at a sufficiently early stage of development has not yet been found. Cathepsin D (CD) is lysosomal aspartyl proteinase. It is a component of a proteolytic cascade participating actively in neoplastic invasion as well as in metastasis formation. Carcino-embryonic antigen (CEA) is a useful marker in oncological diagnostics of colorectal cancer. CEA undergoes expression in all kinds of adenocarcinoma and is found both intercellularly and extracellularly. High concentrations of CEA in the blood serum confirm neoplastic changes in the digestive tract with high probability. The objective of this study has been to evaluate CD activity in the blood serum, urine and tumor tissues as well as in the colon biopsies which were not changed macroscopically and CEA concentration in the serum of colon adenocarcinoma, considering the extent of spread of cancer (TNM), the grade of the differentiation of cancer cell (G) as well as the tumor size. The possibility of application of CD along with CEA as markers of colon adenocarcinoma has also been examined. METHODOLOGY: The examination included the serum and urine of 21 patients as well as 12 tissues biopsies with histopathologically confirmed colon adenocarcinoma. The reference group for the blood and urine comprised of 17 healthy controls, and for the colon adenocarcinoma tissues- samples collected from 14 people from the sites most distant from the resected tumor on the boundaries which were free of cancer cells. Activity of CD in the blood serum, urine as well as tissues was determined with a modified Greczaniuk et al. method and expressed by the amount of released tyrosine as the concentration of the activity in nmolTyr/mL/6h, whereas the specific activity was expressed in nmol Tyr/mg of protein /6h. The specific activity of CD in the urine was expressed in nmol Tyr/mg of creatinine/6h. CEA concentration in the blood serum was determined by the immunoenzymatic method (MEIA) on Axym Abbot Analyzer and was expressed in ng/mL. The protein concentration was determined by the Lowry method, and the results were expressed in mg/mL. The creatinine concentration in the urine was determined by the Jaffe method (without deproteinization) and was expressed in mg/100mL. RESULTS: CD activity was increased in the blood serum (p < 0.0001) and tissues (p = 0.022) of colon adenocarcinoma patients in comparison to the reference group. CD specific activity (Tyr/mg of protein/6h) was significantly increased in serum but decreased in the urine (p < 0.0001) whereas the specific activity of CD (nmol Tyr/mg of creatinine/6h) was increased in the urine (p = 0.0001). CD specific activity has tendency to increase in colon adenocarcinoma tissues (p = 0.441) as compared to the reference group. By examining data in regard to TNM clinical-histopathological classification, G and the tumor size, it could be concluded that CD activity in serum and urine in colon adenocarcinoma patients depends on progress of cancer in which CD activity increases with TNM. A statistically significant increase in CEA concentration was found in the serum of colon adenocarcinoma patients, which was almost threefold higher than the in reference group. No significant differences in CEA concentration were found depending on TNM, G and tumor size. CONCLUSIONS: The results of this study suggest that examination of CD activity and CEA concentration in serum, as well as CD activity in the urine, might be used in oncological diagnostics of colon adenocarcinoma.
机译：背景/目的：肿瘤标志物在大肠癌的早期诊断中的应用为数百万患者带来了新希望。然而，尚未发现这种标志物，其对于该特定癌是独特的，并且可以在发育的足够早期进行检测。组织蛋白酶D（CD）是溶酶体天冬氨酰蛋白酶。它是蛋白水解级联的一个组成部分，积极参与肿瘤的侵袭和转移形成。癌胚抗原（CEA）在大肠癌的肿瘤学诊断中是有用的标记。 CEA在各种腺癌中均表达，并且在细胞内和细胞外都发现。血清中高浓度的CEA很有可能证实消化道肿瘤的改变。这项研究的目的是评估在血清，尿液和肿瘤组织以及结肠活检组织中CD活性，这些活性在宏观上没有改变，并且考虑到癌扩散的程度，结肠腺癌血清中的CEA浓度（ TNM），癌细胞（G）的分化程度以及肿瘤大小。还研究了将CD和CEA一起用作结肠腺癌标志物的可能性。方法：检查包括21例患者的血清和尿液，以及12例经病理组织学确认的结肠腺癌的活组织检查。血液和尿液的参考组由17个健康对照组成，结肠腺癌组织的参考组是从14个人中收集的，这些人来自最远离切除肿瘤边界的无癌细胞的部位。用改良的Greczaniuk等人的方法测定血清，尿液和组织中CD的活性。该方法以酪氨酸释放量表示为活性的浓度，单位为nmolTyr / mL / 6h，而比活则以nmol Tyr / mg的蛋白质/ 6h表示。尿液中CD的比活性以nmol Tyr / mg肌酐/ 6h表示。通过Axym Abbot Analyzer上的免疫酶法（MEIA）测定血清中的CEA浓度，并以ng / mL表示。用Lowry法测定蛋白质浓度，结果以mg / mL表示。尿液中的肌酐浓度通过Jaffe方法（无脱蛋白）测定，以mg / 100mL表示。结果：与参考组相比，结肠腺癌患者的血清（p <0.0001）和组织（p = 0.022）的CD活性增加。血清中CD的比活性（Tyr / mg蛋白/ 6h）明显增加，但尿液中则降低（p <0.0001），而尿中CD的比活性（nmol Tyr / mg肌酐/ 6h）增加（p = 0.0001）。与参考组相比，结肠癌组织中的CD比活性具有增加的趋势（p = 0.441）。通过检查有关TNM临床组织病理学分类，G和肿瘤大小的数据，可以得出结论，结肠腺癌患者血清和尿液中的CD活性取决于癌症的进展，其中CD活性随TNM增加。在结肠腺癌患者的血清中发现CEA浓度有统计上的显着增加，几乎是参考组的三倍。根据TNM，G和肿瘤大小，未发现CEA浓度有显着差异。结论：这项研究的结果表明，检查血清中CD活性和CEA浓度以及尿液中CD活性的检查可用于结肠腺癌的肿瘤学诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号